Applied DNA Sciences (APDN)
(Delayed Data from NSDQ)
$1.91 USD
-0.30 (-13.57%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $1.82 -0.09 (-4.71%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for Applied DNA Sciences Inc falls in the month of September.
All items in Millions except Per Share data.
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 7 | 15 | 7 | 8 | 1 |
Receivables | 0 | 3 | 3 | 0 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 1 | 1 | 1 | 0 |
Other Current Assets | 0 | 1 | 1 | 1 | 1 |
Total Current Assets | 8 | 20 | 11 | 9 | 2 |
Net Property & Equipment | 1 | 2 | 3 | 1 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 3 | 0 | 0 | 1 | 1 |
Deposits & Other Assets | 1 | 0 | 0 | 0 | 0 |
Total Assets | 14 | 22 | 14 | 11 | 4 |
Liabilities & Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 2 | 0 |
Accounts Payable | 2 | 4 | 3 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 0 | 1 | 1 |
Total Current Liabilities | 3 | 4 | 3 | 4 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 2 |
Long-Term Debt | 0 | 0 | 0 | 1 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4 | 5 | 0 | 1 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 9 | 9 | 3 | 6 | 4 |
Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 307 | 305 | 295 | 276 | 256 |
Retained Earnings | -302 | -293 | -284 | -270 | -257 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 5 | 13 | 11 | 6 | -1 |
Total Liabilities & Shareholder's Equity | 14 | 22 | 14 | 11 | 4 |
Total Common Equity | 5 | 13 | 11 | 6 | -1 |
Shares Outstanding | 0.60 | 0.60 | 0.30 | 0.20 | 0.00 |
Book Value Per Share | 8.12 | 21.52 | 37.03 | 28.55 | -0.85 |
Fiscal Year End for Applied DNA Sciences Inc falls in the month of September.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 10 | 3 | 3 | 7 | 11 |
Receivables | 1 | 0 | 0 | 0 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 0 | 0 | 1 |
Total Current Assets | 12 | 4 | 5 | 8 | 12 |
Net Property & Equipment | 1 | 0 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 3 | 3 | 3 | 3 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 17 | 9 | 10 | 14 | 16 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 2 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 3 | 3 | 3 | 3 | 3 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 1 | 1 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 2 | 4 | 5 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 4 | 9 | 6 | 9 | 9 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 319 | 308 | 308 | 307 | 306 |
Retained Earnings | -306 | -308 | -304 | -302 | -299 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 12 | 0 | 4 | 5 | 7 |
Total Liabilities & Shareholder's Equity | 17 | 9 | 10 | 14 | 16 |
Total Common Equity | 12 | 0 | 4 | 5 | 7 |
Shares Outstanding | 10.20 | 0.80 | 0.60 | 0.60 | 0.60 |
Book Value Per Share | 1.20 | -0.23 | 6.88 | 8.12 | 11.98 |